Immunological efficacy of glycoconjugates derived from Vibrio cholerae O1 serotype Ogawa detoxified LPS in mice.
This study focused on changes in selected parameters of humoral and cellular immunity following vaccination of mice with unique Vibrio cholerae LPS-protein-complexed conjugates. The V. cholerae detoxified LPS (dLPS)-derived antigenic structures O-specific polysaccharide (O-SP) and de-O-acylated LPS (DeOAc-LPS) were used to prepare glycoconjugates by linking both dLPSs to glucan, the immunomodulating matrix, and then to BSA carrier. Animals were given a primary vaccination and boosted at 2-week intervals with a dose of 4.5 μg saccharide antigen. The last boost was given either subcutaneously or intraperitoneally (i.p.) to compare the boosting effect and to optimize the effective immunization route. Both conjugates (O-SP-BSA and DeOAc-LPS-BSA) induced significant levels of antigen-specific Ig isotypes, especially IgG and IgM. The i.p. booster route was more effective. A T helper 1 response was achieved only by immunization with O-SP-BSA conjugate administered i.p. Significant acceleration of phagocytic capacity and respiratory burst of neutrophils was demonstrated by both immunogenic formulations. Activation of T- and B-cell adaptive immunities was exhibited as specific changes in CD3 : CD19 and CD4 : CD8 ratios, B-cell low-affinity Fcγ II and III receptor expression and induction of CD45R antigen.
Paulovičová
Ema
E
Slovak Academy of Sciences, Institute of Chemistry, Centre of Excellence GLYCOMED, Dubravska cesta 9, 84236 Bratislava, Slovakia.
Korcová
Jana
J
Slovak Academy of Sciences, Institute of Chemistry, Centre of Excellence GLYCOMED, Dubravska cesta 9, 84236 Bratislava, Slovakia.
Farkaš
Pavol
P
Slovak Academy of Sciences, Institute of Chemistry, Centre of Excellence GLYCOMED, Dubravska cesta 9, 84236 Bratislava, Slovakia.
Bystrický
Slavomír
S
Slovak Academy of Sciences, Institute of Chemistry, Centre of Excellence GLYCOMED, Dubravska cesta 9, 84236 Bratislava, Slovakia.
D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial; D022121:Cholera Vaccines / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D006001:Glycoconjugates / Q000276:immunology*; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008070:Lipopolysaccharides / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D014734:Vibrio cholerae / Q000276:immunology / Q000378:metabolism*
D000907:Antibodies, Bacterial; D022121:Cholera Vaccines; D006001:Glycoconjugates; D008070:Lipopolysaccharides